TIAA CREF Investment Management’s Crescent Biopharma CBIO Stock Holding History

TIAA CREF Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$892K	Buy	716 +69	+11%	+$79K	﹤0.01%	2379
2018 Q4	$613K	Sell	647 -6	-0.9%	-$7.22K	﹤0.01%	2482
2018 Q3	$940K	Sell	653 -94	-13%	-$142K	﹤0.01%	2447
2018 Q2	$1.21M	Buy	+747	New	+$1.28M	﹤0.01%	2416
2017 Q2	–	Sell	-309	Closed	-$168K	–	3148
2017 Q1	$168K	Sell	309 -4	-1%	-$2.46K	﹤0.01%	3014
2016 Q4	$191K	Hold	313	–	–	﹤0.01%	3048
2016 Q3	$224K	Sell	313 -15	-5%	-$11.5K	﹤0.01%	3039
2016 Q2	$238K	Buy	+328	New	+$226K	﹤0.01%	3070
2014 Q2	–	Sell	-323	Closed	-$528K	–	3135
2014 Q1	$528K	Buy	+323	New	+$391K	﹤0.01%	2921

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TIAA CREF Investment Management's CBIO Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Crescent Biopharma (CBIO) stake by 11% in Q1 2019, buying an estimated $79K and bringing the position to 716 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

TIAA CREF Investment Management first reported a position in CBIO in Q1 2014 and has held it in 9 quarters since. The position peaked at $1.21M in Q2 2018. 77 funds tracked by Wall St. Rank hold CBIO as of Q1 2019.

TIAA CREF Investment Management held 716 shares of Crescent Biopharma worth $892K as of Q1 2019.
TIAA CREF Investment Management bought 69 Crescent Biopharma shares in Q1 2019, an estimated $79K.
Crescent Biopharma made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2379 holding.
TIAA CREF Investment Management first reported a position in Crescent Biopharma in Q1 2014 and has held it in 9 quarters since.
TIAA CREF Investment Management's Crescent Biopharma position peaked at $1.21M in Q2 2018.
77 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.